Rapid molecular testing for clinical diagnostics
Abacus Diagnostica’s proprietary, fully automated testing platform GenomEra® CDX takes molecular testing to a new level of easiness and speed without compromising the quality of results.
Cost efficient automated solution
All-in-one PCR and RT-PCR test chips with homogeneous detection in fully automated instrument.
Reducing the costs by affordable pricing, robust assays and long service intervals.
CE IVD tests for infectious diseases
Critical human pathogens and antibiotic resistance markers such as C. difficile, Norovirus and MRSA
Our products
GenomEra CDX system has proven to be one of the fastest, easiest-to-use and the most cost-effective automated solution for molecular diagnostics (MDx) of infectious diseases. GenomEra is suitable also for small to mid-size customers without any prior experience in MDx.
News
-
Diagnostics pioneers Abacus Diagnostica, Kaivogen and Labrox are now together Uniogen
Three Finnish life science experts – Abacus Diagnostica, a frontrunner in molecular testing and rapid PCR test systems, Kaivogen, a specialist in immunoassays and antibody tests, and Labrox, an innovator of high technology laboratory instruments and diagnostic readers – announced in September 2021 that they are joining forces to form a global diagnostics pioneer. The share swap agreement between the companies has entered into force and the transaction has now been completed. The name of the new company is Uniogen Oy. The company is targeting the global market with a total solution under development for point-of-care testing for infectious diseases and cancers, among others.
READ MORE
-
GenomEra® 2.0 assay kit for COVID-19 CE marked – introduces second-generation usability and sensitivity to PCR testing
Abacus Diagnostica, part of Uniogen, is launching its second-generation COVID-19 test, the GenomEra® SARS-CoV-2 2.0 Assay Kit in the European market. The assay kit has recently received European CE marking for In Vitro Diagnostic (IVD) medical devices.
It is intended for healthcare professionals, and it detects the SARS-CoV-2 virus in respiratory samples in 50 minutes.
- The assay kit provides rapid PCR test results with excellent sensitivity (98.3%) and high specificity (99.8%).
- The sample is collected to an inactivating sample collection media, which means that neither extensive safety measures nor dedicated PCR facilities are required.
- After a short and simple sample preparation, the assay process is fully automated. The results are automatically interpreted after 50 minutes. With one GenomEra® test system, up to four samples can be analysed at the same time. Capacity can be extended to 32 samples by combining up to eight instruments.
- The test performance is not affected by emergence of different COVID-19 variants, as the test simultaneously detects two different targets in the SARS-CoV-2 virus genome
– the RdRp and E genes.
More information: SARS-CoV-2 2.0
- The assay kit provides rapid PCR test results with excellent sensitivity (98.3%) and high specificity (99.8%).
-
Abacus Diagnostica, Kaivogen ja Labrox yhdistyvät
Abacus Diagnostica, Kaivogen ja Labrox yhdistyvät ja muodostavat edelläkävijän globaaleille diagnostiikkamarkkinoille – Tavoitteena oikea diagnoosi sekä hoito ensimmäisellä potilaskäynnillä
Turkulaiset biotekniikan huippuosaajat Abacus Diagnostica, Kaivogen ja Labrox ovat yhdistymässä kansainväliseksi diagnostiikkaratkaisujen edelläkävijäksi. Uusi yhtiö tulee tarjoamaan globaaleille markkinoille ainutlaatuisen vieritestauksen kokonaisratkaisun muun muassa infektio- ja syöpäsairauksien diagnostiikkaan. Se tuo yhteen maailman kärkeä olevan laite- ja kemiaosaamisen sekä tarjoaa terveydenhuollolle ja potilaille entistä nopeampaa, helpompaa ja kustannustehokkaampaa sairauksien tunnistamista. Yhdistyminen on tarkoitus saada päätökseen lokakuussa. Yhtiön nimi tullaan päättämään kuluvan syksyn aikana.
Taustalla olevilla kasvuyhtiöllä on vuosien kokemus diagnostiikan markkinoista: Abacus Diagnostica on molekyylitestauksen ja pika-PCR-testijärjestelmien suunnannäyttäjä, Kaivogen on immunomääritysten ja vasta-ainetestien erikoisosaaja ja Labrox on innovatiivinen laboratorioinstrumenttien kehittäjä.
Abacus Diagnostica, Kaivogen and Labrox joining forces to form a global diagnostics pioneer – Enabling the right diagnosis and care at the patient’s first appointment
Three Finnish biotech companies – Abacus Diagnostica, Kaivogen, and Labrox – are joining forces to form an international frontrunner in in vitro diagnostics. The new company will provide the global market with a unique total solution for point-of-care testing, including diagnostics for infectious diseases and cancers. It brings together some of the world’s leading instrumentation and biochemical knowhow, and it will offer healthcare providers and patients faster, easier and more cost-effective diagnostics. The transaction is to be completed in October. The name of the company will be decided during this autumn.
The three growth companies have years of experience in diagnostics: Abacus Diagnostica is a frontrunner in molecular testing and rapid PCR tests, Kaivogen specialises in immunoassays and antibody tests, and Labrox is an innovative developer of laboratory instruments.
